BioRestorative Therapies Inc (BRTX) - Total Assets
Based on the latest financial reports, BioRestorative Therapies Inc (BRTX) holds total assets worth $4.64 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can BioRestorative Therapies Inc service its debt to assess how comfortably operating cash covers total debt obligations.
BioRestorative Therapies Inc - Total Assets Trend (2009–2025)
This chart illustrates how BioRestorative Therapies Inc's total assets have evolved over time, based on quarterly financial data. See BioRestorative Therapies Inc (BRTX) net assets for net asset value and shareholders' equity analysis.
BioRestorative Therapies Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
BioRestorative Therapies Inc's total assets of $4.64 Million consist of 76.9% current assets and 23.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 37.0% |
| Accounts Receivable | $15.50K | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $534.20K | 13.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2009–2025)
This chart illustrates how BioRestorative Therapies Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BRTX market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioRestorative Therapies Inc's current assets represent 76.9% of total assets in 2025, an increase from 0.0% in 2009.
- Cash Position: Cash and equivalents constituted 37.0% of total assets in 2025, up from 0.0% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, a decrease from 98.0% in 2009.
- Asset Diversification: The largest asset category is intangible assets at 13.1% of total assets.
BioRestorative Therapies Inc Competitors by Total Assets
Key competitors of BioRestorative Therapies Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
BioRestorative Therapies Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.35 | 2.24 | 1.38 |
| Quick Ratio | 2.35 | 2.24 | 1.38 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.19 Million | $5.17 Million | $502.46K |
BioRestorative Therapies Inc - Advanced Valuation Insights
This section examines the relationship between BioRestorative Therapies Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.52 |
| Latest Market Cap to Assets Ratio | 1.28 |
| Asset Growth Rate (YoY) | -66.8% |
| Total Assets | $4.08 Million |
| Market Capitalization | $5.22 Million USD |
Valuation Analysis
Above Book Valuation: The market values BioRestorative Therapies Inc's assets above their book value (1.28x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: BioRestorative Therapies Inc's assets decreased by 66.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for BioRestorative Therapies Inc (2009–2025)
The table below shows the annual total assets of BioRestorative Therapies Inc from 2009 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $4.08 Million | -66.78% |
| 2024-12-31 | $12.28 Million | -2.63% |
| 2023-12-31 | $12.61 Million | -23.26% |
| 2022-12-31 | $16.43 Million | -26.81% |
| 2021-12-31 | $22.45 Million | +416.52% |
| 2020-12-31 | $4.35 Million | +196.46% |
| 2019-12-31 | $1.47 Million | +22.97% |
| 2018-12-31 | $1.19 Million | -32.20% |
| 2017-12-31 | $1.76 Million | +11.30% |
| 2016-12-31 | $1.58 Million | -21.67% |
| 2015-12-31 | $2.02 Million | +19.22% |
| 2014-12-31 | $1.69 Million | +22.34% |
| 2013-12-31 | $1.38 Million | +9.06% |
| 2012-12-31 | $1.27 Million | +473.85% |
| 2011-12-31 | $220.97K | -52.83% |
| 2010-12-31 | $468.51K | -93.98% |
| 2009-12-31 | $7.79 Million | -- |
About BioRestorative Therapies Inc
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected fro… Read more